Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL619621 | 1.00 | RAD52 (0.39) | RAD52EGFRBRAFHSD11B1KDM4E | |
| SCHEMBL620252 | 0.89 | HSD11B1 (0.44) | RAD52EGFRBRAFHSD11B1KDM4E | |
| SCHEMBL620251 | 0.89 | HSD11B1 (0.44) | RAD52EGFRBRAFHSD11B1KDM4E | |
| SCHEMBL7825613 | 0.86 | HSD11B1 (0.44) | RAD52EGFRBRAFHSD11B1KDM4E | |
| SCHEMBL6558688 | 0.86 | HSD11B1 (0.44) | RAD52EGFRBRAFHSD11B1KDM4E | |
| SCHEMBL7818526 | 0.84 | KDM4E (0.44) | RAD52EGFRBRAFHSD11B1KDM4E | |
| SCHEMBL6559980 | 0.84 | KDM4E (0.44) | RAD52EGFRBRAFHSD11B1KDM4E | |
| SCHEMBL617133 | 0.83 | KDM4E (0.49) | RAD52EGFRBRAFKDM4EHTT | |
| SCHEMBL617134 | 0.83 | KDM4E (0.49) | RAD52EGFRBRAFKDM4EHTT | |
| SCHEMBL619822 | 0.80 | KDM4E (0.43) | RAD52KDM4EHTTATMHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277259-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-11-01 | — | — | US | disclosed |
| US-20120041011-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-02-16 | — | — | US | disclosed |
| US-20110021549-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-01-27 | — | — | US | disclosed |
| US-7842703-B2 | Substituted benzofused derivatives and their use as vanilloid receptor ligands | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-11-30 | — | — | US | disclosed |
| US-20080269253-A1 | Substituted Benzofused Derivatives and Their Use as Vanilloid Receptor Ligands | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269253-A1 | Substituted Benzofused Derivatives and Their Use as Vanilloid Receptor Ligands | TRPV1, GPR17, TRPV6 | RAD52 4649/4885EGFR 612/4885BRAF 2243/4885 |
| US-20120041011-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | TRPV1, GPR17, TRPV6 | RAD52 4642/4885EGFR 599/4885BRAF 2142/4885 |
| US-20110021549-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | TRPV1, GPR17, TRPV6 | RAD52 4642/4885EGFR 599/4885BRAF 2142/4885 |
| US-20120277259-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | TRPV1, GPR17, TRPV6 | RAD52 4649/4885EGFR 612/4885BRAF 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.